32

Literatur

Eigene Artikel als Erstautor

E1. Lein M, Jung K, Schnorr D, Henke W, Loening SA: "Strip test for the quick detection of increased concentrations of prostate-specific antigen in blood." Eur J Clin Chem Clin Biochem. 1996; 34: S.511-514.

E2. Lein M, Stephan C, Jung K, Schnorr D, Loening SA: "Relation of free PSA/total PSA in serum for differentiating between patients with prostatic cancer and benign hyperplasia of the prostate: which cutoff should be used" ? Cancer Invest. 1998; 16: S.45-49.

E3. Lein M, Koenig F, Jung K, McGovern FJ, Skates SJ, Schnorr D, Loening SA: "The percentage of free prostate specific antigen is an age-independent tumour marker for prostate cancer: establishment of reference ranges in a large population of healthy men" . Br J Urol. 1998; 82: S.231-236.

E4. Lein M, Brux B, Jung K, Henke W, Koenig F, Stephan C, Schnorr D, Loening SA: "Elimination of serum free and total prostate-specific antigen after radical retropubic prostatectomy" . Eur J Clin Chem Clin Biochem. 1997; 35: S.591-595.

E5. Lein M, Jung K, Brux B, Knäbich A, Sinha P, Schnorr D, Loening SA: "Re: Free and complexed prostate specific antigen in the differentiation of benign prostatic hyperplasia and prostate cancer: studies in serum and plasma samples." J Urol. 1999; 162: S.502-503.

E6. Lein M, Jung K, Elgeti U, Petras T, Stephan C, Brux B, Sinha P, Winkelmann B, Schnorr D, Loening SA: "Comparison of the clinical validity of free-prostate specific antigen, alpha-1-antichymotrypsin-prostate specific antigen and complexed-prostate specific antigen in prostate cancer diagnosis" . Eur Urol , eingereicht. 12/99;

E7. Lein M, Jung K, Hammerer P, Graefen M, Semjonow A, Stieber P, Ossendorf M, Luboldt HJ, Brux B, Stephan C, Schnorr D, Loening SA: "A multicenter clinical trial on the use of alpha-1-antichymotrypsin-prostate-specific antigen in prostate cancer diagnosis." Prostate 2001; 47:

E8. Lein M, Stephan C, Jung K, Schnorr D, Loening SA ": Molekulare Formen des prostataspezifischen Antigens und des humanen Kallikreins 2 als mögliche Indikatoren in der Prostatakarzinomdiagnostik" . Urol A. 2000; 39: S.313-323.

E9. Lein M, Jung K, Weiß S, Schnorr D, Loening SA ": Soluble CD44 variants in serum of patients with urological malignancies." Oncology. 1997; 54: S.226-230.

E10. Lein M, Nowak L, Jung K, Koenig F, Lichtinghagen R, Schnorr D, Loening SA: "Analytical aspects regarding the measurement of metalloproteinases and their inhibitors in blood" . Clin Biochem. 1997; 30: S.491-496.

E11. Lein M, Jung K, Laube Ch, Hübner T, Winkelmann B, Stephan C, Hauptmann S, Rudolph B, Schnorr D, Loening SA ": Matrix-Metalloproteinases and their inhibitors in plasma and tumor tissue of patients with renal cell carcinoma." Int J Cancer . 2000; 85: S.801-804.

E12. Lein M, Nowak L, Jung K, Laube Ch, Ulbricht N, Schnorr D, Loening SA ": Metalloproteinases and tissue inhibitors of matrix-metalloproteinases in plasma of patients with prostate cancer and in prostate cancer tissue. " Ann NY Acad Sci. 1999; 878: S.544-546.

E13. Lein M, Koenig F, Misdraji J, McDougal WS, Jung K, Loening SA, Hasan T, Ortel B ": Laser-induced hyperthermia in rat prostate cancer: role of site of tumor implantation." Urology. 2000; 56: S.167-172.

E14. Lein M, Jung K, Le DK, Hasan T, Ortel B, Borchert D, Winkelmann B, Schnorr D, Loening SA: "Synthetic inhibitor of matrix metalloproteinases (Batimastat) reduces the prostate cancer growth in an orthotopic rat model" . Prostate. 2000; 43: S.77-82.

33

Eigene Artikel als Koautor

K1. Jung K, Zachow J, Lein M, Brux B, et al ".: Rapid detection of elevated prostate-specific antigen levels in blood: performance of various membrane strip test compared." Urology . 1999; 53: S.155-160.

K2. Stephan C, Lein M, Jung J, Schnorr D, et al ".: The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia. " Cancer. 1997; 79: S.104-109.

K3. Jung K, Meyer A, Lein M, Rudolph B, et al ".: Ratio of free to total prostate specific antigen in serum can not distinguish patients with prostate cancer from those with chronic inflammation of the prostate." J Urol. 1998; 159: S.1595-1598.

K4. Meyer A, Jung K, Lein M, Schnorr D, et al ".: Factors influencing the ratio of free to total prostate specific antigen in serum." Int J Cancer. 1997; 74: S.630-636.

K5. Stephan C, Jung K, Brux B, Lein M, et al ".: ACT-PSA and complexed PSA elimination kinetics in serum after radical retropubic prostatectomy: proof of new complex forming of PSA after release into circulation. " Urology. 2000; 55: S.560-563.

K6. Jung K, Brux B, Lein M, Knäbich A, et al ".: Determination of alpha1-antichymotrypsin-PSA complex in serum does not improve the differentiation between benign prostatic hyperplasia and prostate cancer compared with total PSA and percent free PSA." Urology. 1999; 53: S.1160-1168.

K7. Jung K, Elgeti U, Lein M, Brux B, et al ".: Ratio of free or complexed prostate-specific antigen (PSA) to total PSA: which ratio improves differentiation between benign prostatic hyperplasia and prostate cancer?. " Clin Chem . 2000; 46: S.55-62.

K8. Jung K, Lein M, Weiss S, Schnorr D, et al.: " Soluble CD44 molecules in serum of patients with prostate cancer and benign prostatic hyperplasia. " Eur J Cancer. 1996; 32: S.627-630.

K9. Lein M, Weiss S, Jung K, Schnorr D, et al ".: Soluble CD44 variants in serum of patients with prostate cancer and other urological malignancies." Prostate. 1996; 29: S.334-335.

K10. Lein M, Jung K, Nowak L, Schnorr D, et al ".: Analytical aspects regarding the measurement of metalloproteinases. " Ann NY Acad Sci. 1999; 878: S.491-493.

K11. Jung K, Laube C, Lein M, Lichtinghagen R, et al ".: Kind of sample as preanalytical determinant of matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinase 2 in blood." Clin Chem. 1998; 44: S.1060-1062.

K12. Jung K, Nowak L, Lein M, Henke W, et al.: " What kind of specimen should be selected for determining tissue inhibitor of metalloproteinase-1 (TIMP-1) in blood? " Clin Chim Acta. 1996. 254; 97-100.:

K13. Jung K, Nowak L, Lein M, Priem F, et al ".: Matrix metalloproteinases 1 and 3, tissue inhibitor of metalloproteinase 1 and the complex of metalloproteinase 1/tissue inhibitor in plasma of patients with prostate cancer. " Int J Cancer (Pred Oncol). 1997; 74: S.220-223.

K14. Jung K, Lein M, Ulbrich N, Rudolph B, et al ".: Quantification of matrix metalloproteinases and tissue inhibitors of metalloproteinase in prostatic tissue: analytical aspects" . Prostate. 1998; 34: S.130-136.

Literatur

1. Greenlee RT, Murray T, Bolden S, Wingo PA: "Cancer statistics, 2000. " CA Cancer J Clin. 2000, 50: S.7-33.

2. Gee WF, Holtgrewe L, Albertsen PC, et al.: "Practice trends in the diagnosis and management of prostate cancer of prostate cancer. " J Urol. 1995, 154: S.207-208.

3. Polascik TJ, Oesterling JE, Partin AW: "Prostate specific antigen: a decade of discovery-what we have learned and where we are going. " J Urol . 1999, 162: S.293-306.

34

4. Lilja H: "Seminal vesicle-secreted proteins and their reactions during gelation and liquefaction of human semen. " J Clin Invest. 1987, 80: S.281-285.

5. Armbruster DA: "Prostate-specific antigen: biochemistry, analytical methods, and clinical application. " Clin Chem . 1993, 39: S.181-195.

6. Wang MC, Valenzuela LA, Murphy GP, Chu TM ": Purification of a human prostate specific antigen. " Invest Urol. 1979, 17: S.159-163.

7. Stenman UH, Leinonen J, Zhang WM, Finne P: "Prostate-specific antigen. " Semin Cancer Biol. 1999, 9: S.83-93.

8. Catalona WJ, Smith DS, Ratliff TL, Basler JW: "Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. " JAMA. 1993, 270: S.948-954.

9. Mettlin CJ, Murphy GP, Ho R, Menck HR: "The National Cancer Database report on longitudinal observations on prostate cancer. " Cancer. 1996, 77: S.2162-2166.

10. Epstein JI, Walsh PC, Carmichael M, Brendler CB: "Pathologic and clinical findings to predict tumor extent of non-palpable (stage T1c) prostate cancer. " JAMA. 1994, 271: S.368-374.

11. Brawer MK, Chetner MP, Beatie J, et al.: "Screening for prostatic carcinoma with prostate specific antigen. " J Urol. 1992, 147: S.841-845.

12. Catalona WJ, Richie JP, Ahmann FR, et al.: "Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. " J Urol. 1994, 151: S.1283-1290.

13. Cooner WH, Mosley BR, Rutherford CL, Jr., et al.: "Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. " J Urol. 1990, 143: S.1146-1152.

14. Labrie F, Dupont A, Suburu R, et al.: "Serum prostate specific antigen as pre-screening test for prostate cancer. " J Urol. 1992, 147: S.846-851.

15. Bunting PS: "A guide to the interpretation of serum prostate specific antigen levels. " Clin Biochem. 1995, 28: S.221-241.

16. Brawer MK: "Prostate-specific antigen. " Semin Surg Oncol. 2000, 18: S.3-9.

17. Nixon RG, Brawer MK: "Enhancing the specificity of prostate-specific antigen (PSA): an overview of PSA density, velocity and age-specific reference ranges. " Br J Urol. 1997, 79(Suppl 1): S.61-67.

18. Ukimura O, Durrani O, Babaian RJ: "Role of PSA and its indices in determining the need for repeat prostate biopsies. " Urology. 1997, 50: S.66-72.

19. Stenman UH, Leinonen J, Alfthan H, et al.: "A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. " Cancer Res. 1991, 51: S.222-226.

20. Leinonen J, Zhang WM, Stenman UH: "Complex formation between PSA isoenzymes and protease inhibitors. " J Urol. 1996, 155: S.1099-1103.

21. Catalona WJ, Partin AW, Slawin KM, et al.: "Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. " JAMA. 1998, 279: S.1542-1547.

22. Chen YT, Luderer AA, Thiel RP, et al.: "Using proportions of free to total prostate-specific antigen, age, and total prostate-specific antigen to predict the probability of prostate cancer. " Urology. 1996, 47: S.518-524.

23. Bangma CH, Kranse R, Blijenberg BG, Schroder FH: "The free-to-total serum prostate specific antigen ratio for staging prostate carcinoma. " J Urol. 1997, 157: S.544-547.

24. Van Cangh PJ, De Nayer P, De Vischer L, et al.: "Free to total prostate-specific antigen (PSA) ratio improves the discrimination between prostate cancer and benign prostatic hyperplasia (BPH) "

35

25. Woodrum DL, Brawer MK, Partin AW, et al.: "Interpretation of free prostate specific antigen clinical research studies for the detection of prostate cancer. " J Urol. 1998, 159: S.5-12.

26. Björk T, Bjartell A, Abrahamsson PA, et al.: "Alpha 1-antichymotrypsin production in PSA-producing cells is common in prostate cancer but rare in benign prostatic hyperplasia. " Urology. 1994, 43: S.427-434.

27. Stenman UH: "Prostate-specific antigen, clinical use and staging: an overview. " Br J Urol. 1997, 79(Suppl 1): S.53-60.

28. Huber PR, Schmid HP, Mattarelli G, et al.: "Serum free prostate specific antigen: isoenzymes in benign hyperplasia and cancer of the prostate. " Prostate. 1995, 27: S.212-219.

29. Wu JT, Wilson L, Zhang P, et al.: "Correlation of serum concentrations of PSA-ACT complex with total PSA in random and serial specimens from patients with BPH and prostate cancer. " J Clin Lab Anal. 1995, 9: S.15-24.

30. Espana F, Royo M, Martinez M, et al.: "Free and complexed prostate specific antigen in the differentiation of benign prostatic hyperplasia and prostate cancer: studies in serum and plasma samples. " J Urol. 1998, 160: S.2081-2088.

31. Wu JT, Zhang P, Liu GH, Wilson L: "Development of an immunoassay specific for the PSA-ACT complex without the problem of high background. " J Clin Lab Anal. 1998, 12: S.14-19.

32. Heidtmann HH, Havemann K: "Assay of complexed alpha 1-antichymotrypsin in plasma. " Clin Chem. 1993, 39: S.869-874.

33. Björk T, Piironen T, Pettersson K, et al.: "Comparison of analysis of the different prostate-specific antigen forms in serum for detection of clinically localized prostate cancer. " Urology. 1996, 48: S.882-888.

34. Christensson A, Bjork T, Nilsson O, et al.: "Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer. " J Urol. 1993, 150: S.100-105.

35. Partin AW, Brawer MK, Subong ENP, et al.: "Prospective evaluation of percent free-PSA and complexed-PSA for early detection of prostate cancer. " Prostate Cancer Prostatic Diseases. 1998, 1: S.197-203.

36. Brawer MK, Meyer GE, Letran JL, et al.: "Measurement of complexed PSA improves specificity for early detection of prostate cancer. " Urology. 1998, 52: S.372-378.

37. Allard WJ, Zhou Z, Yeung KK: "Novel immunoassay for the measurement of complexed prostate-specific antigen in serum. " Clin Chem. 1998, 44: S.1216-1223.

38. Gann PH, Hennekens CH, Stampfer MJ: "A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. " JAMA. 1995, 273: S.289-294.

39. Oesterling JE, Jacobsen SJ, Chute CG, et al.: "Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. " JAMA. 1993, 270: S.860-864.

40. Partin AW, Catalona WJ, Southwick PC, et al.: "Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume, and age. " Urology. 1996, 48: S.55-61.

41. Richardson TG, Wojno KJ, Liang LW, et al.: "Half-life determination of serum free prostate-specific antigen following radical retropubic prostatectomy. " Urology. 1996, 48: S.40-44.

42. Partin AW, Piantadosi S, Subong ENP, et al.: "Clearence rate of serum-free and total PSA following radical retropubic prostatectomy. " Prostate. 1996, 7(suppl): S.35-39.

43. Agha AH, Schechter E, Roy JB, Culkin DJ: "Prostate specific antigen is metabolized in the liver. " J Urol. 1996, 155: S.1332-1335.

44. Kilic S, Yalcinkaya S, Guntekin E, et al.: "Determination of the site of metabolism of total, free, and complexed prostata-specific. " Urology. 1998, 52: S.470-473.

36

45. Filella X, Alcover J, Molina R, et al.: "Measurement of complexed PSA in the differential diagnosis between prostate cancer and benign prostate hyperplasia. " Prostate. 2000, 42: S.181-185.

46. Wang TJ, Linton HJ, Payne J, et al.: "Generation of PSA-ACT-specific monoclonal antibodies and their application in a sandwich immunoassay. " Hybridoma. 1999, 18: S.535-541.

47. Albelda SM: "Biology of disease. Role of integrins and other cell adhesion molecules in tumor progression and metastasis. " Lab Invest. 1993, 68: S.4-17.

48. Stetler-Stevenson WG, Aznavoorian S, Liotta LA: "Tumor cell interactions with extracellular matrix during invasion and metastasis. " Ann Rev Cell Biol. 1993, 9: S.541-573.

49. Aruffo A, Stamenkovic I, Melnick M, et al.: "CD44 is the principal surface receptor for hyaluronate. " Cell. 1990, 61: S.1303-1313.

50. Screaton GR, Bell MV, Bell JI, Jackson DG: "The identification of a new alternative exon with highly restricted tissue expression in transcripts encoding the mouse Pgp-1 (CD44) homing receptor. Comparison of all 10 variable exons between mouse, human and rat. " J Biol Chem. 1993, 268: S.12235-12238.

51. Tölg C, Hofmann M, Herrlich P, Ponta H: "Splicing choice from ten variant exons establishes CD44 variability. " Nucleic Acids Res. 1993, 21: S.1225-1229.

52. Stamenkovic I, Aruffo A, Aminot M, Seed B: "The hematopoietic and epithelial forms of CD44 are distinct polypeptides with different adhesion potential for hyaluronate bearing cells. " EMBO J. 1991, 10: S.343-348.

53. Ponta H, Sleeman J, Herrlich P: "Tumor metastasis formation: cell-surface proteins confer metastasis-promoting or -supressing properties. " Biochim Biophys Acta. 1994, 1198: S.1-10.

54. Heider KH, Hofmann M, Hors E, et al.: "A human homologue of the rat metastatic-associated variant of CD44 is expressed in colorectal carcinomas and adenomatous polyps. " J Cell Biol. 1993, 120: S.227-233.

55. Dall P, Heider KH, Hekele A, et al.: "Surface protein expression and messenger RNA-splicing analysis of CD44 in uterine cervical cancer and normal cervical epithelium. " Cancer Res. 1994, 54: S.3337-3341.

56. Wielenga VJM, Heider KH, Johan G, et al.: "Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression. " Cancer Res. 1993, 53: S.4754-4759.

57. Hofmann M, Rudy W, Zöller M, et al.: "CD44 splice variants confer metastatic behavior in rats: homologous sequences are expressed in human tumor cell lines. " Cancer Res. 1993, 51: S.5292-5297.

58. Guo YJ, Liu G, Wang X, et al.: "Potential use of soluble CD44 in serum as indicator of tumor burden and metastasis in patients with gastric or colon cancer. " Cancer Res. 1994, 54: S.422-426.

59. Liu AY: "Expression of CD44 in prostate cancer cells. " Cancer Lett. 1994, 76: S.63-69.

60. Hong RL, Pu YS, Chu JS, et al.: "Correlation of expression of CD44 isoforms and E-cadherin with differentiation in human urothelial cell lines and transitional cell carcinoma. " Cancer Lett. 1995, 89: S.81-87.

61. Burchardt M, Burchardt T, Shabsigh A, et al.: "Current concepts in biomarker technology for bladder cancer. " Clin Chem. 2000, 46: S.595-605.

62. Gelb AB: "Renal cell carcinoma: current prognostic factors. Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). " Cancer. 1997, 80: S.981-986.

63. Liotta LA, Stetler-Stevenson WG: "Tumor invasion and metastasis: an imbalance of positive and negative regulation. " Cancer Res. 1991, 51(Suppl): S.5054-5059.

64. Twining SS: "Regulation of proteolytic activity in tissues. " Crit Rev Biochem Mol Biol. 1994, 29: S.315-383.

65. Crawford HC, Matrisian LM: "Tumor and stromal expression of matrix metalloproteinases and their "

37

66. Gibbons RP, Cole BS, Richardson RG, et al.: "Regulation of proteolytic activity in tissues. " Crit Rev Biochem Mol Biol. 1994, 29: S.315-383.

67. Anderson IC, Sugarbaker DJ, Ganju RK, et al.: "Stromelysin-3 is overexpressed by stromal elements in primary non-small cell lung cancers and regulated by retinoic acid in pulmonary fibroblasts. " Cancer Res. 1995, 55: S.4120-4126.

68. Murray GI, Duncan ME, O'Neil P, et al.: "Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. " Nat Med. 1996, 2: S.461-462.

69. Davies B, Miles DW, Happerfield LC, et al.: "Activity of type IV collagenases in benign and malignant breast disease. " Brit J Cancer. 1993, 67: S.1126-1131.

70. Powell W, Matrisian L: Complex roles of matrix metalloproteinases in tumor progression. Hrsg.: In: Gunthert U, Birchmeier W, eds: Attempts to understand metastasis formation I: metastasis related molecules. New York: Springer-Verlag, 1996: S.1-21.

71. Zucker S, Lysik RM, DiMassimo BI, et al.: "Plasma assay of gelatinase B: tissue inhibitor of metalloproteinase complexes in cancer. " Cancer. 1995, 76: S.700-708.

72. Stetler-Stevenson WG, Krutzch HC, Liotta LA: "Tissue inhibitor of metalloproteinase (TIMP-2). A new member of the metalloproteinase inhibitor family. " J Biol Chem. 1989, 264: S.17374-17378.

73. Zeng ZS, Huang Y, Cohen AM, Guillem JG: "Prediction of colorectal cancer relapse and survival via tissue RNA levels of matrix metalloproteinase 9. " J Clin Oncol. 1996, 14: S.3133-3140.

74. Brown PD, Giavazzi R: "Matrix metalloproteinase inhibition: a review of anti-tumor activity. " Ann Oncol. 1995, 6: S.967-974.

75. Nagase H: "Matrix metalloproteinases. " Contrib Nephrol. 1994, 107: S.85-93.

76. Tamakoshi K, Kikkawa F, Nawa A, et al.: "Characterization of extracellular matrix-degrading proteinase and its inhibitor in gynecologic cancer tissues with clinically different metastatic form. " Cancer. 1995, 76: S.2565-2571.

77. Stetler Stevenson WG, Hewitt R, Corcoran M: "Matrix metalloproteinases and tumor invasion: from correlation and causality to the clinic. " Semin Cancer Biol. 1996, 7: S.147-154.

78. Zucker S, Mancuso P, DiMassimo B, et al.: "Comparison of techniques for measurement of gelatinases/type IV collagenases: enzyme-linked immunoassays versus substrate degradation assays. " Clin Exp Metastasis. 1994, 12: S.13-22.

79. Stearns M, Stearns ME: "Evidence for increased activated metalloproteinase 2 (MMP-2a) expression associated with human prostate cancer progression. " Oncol Res. 1996, 8: S.69-75.

80. Hamdy FC, Fadlon EJ, Cottam D, et al.: "Matrix metalloproteinase 9 expression in primary prostatic adenocarcinoma and benign prostatic hyperplasia. " Br J Cancer. 1994, 69: S.177-182.

81. Pajouh MS, Nagle RB, Breathnach R, et al.: "Expression of metalloproteinase genes in human prostate cancer. " J Cancer Res Clin Oncol. 1991, 117: S.144-150.

82. Knox JD, Wolf C, McDaniel K, et al.: "Matrilysin expression in human prostate carcinoma. " Mol Carcinog. 1996, 15: S.57-63.

83. Kugler A, Hemmerlein B, Thelen P, et al.: "Expression of metalloproteinase 2 and 9 and their inhibitors in renal cell carcinoma. " J Urol. 1998, 160: S.1914-1918.

84. Powell WC, Knox JD, Navre M, et al.: "Expression of the metalloproteinase matrilysin in DU 145 cells increases their invasive potential in severe combined immunodeficient mice. " Cancer Res. 1993, 3: S.417-422.

85. Lucia MS, Bostwick DG, Bosland M, et al.: "Workgroup I: rodent models of prostate cancer. " Prostate. 1998, 36: S.49-55.

86. Brown PD, Giavazzi R: "Matrix metalloproteinase inhibition: a review of anti-tumor activity. " Ann

38

87. Lokeshwar BL, Selzer MG, Block NL, Gunja-Smith Z: "Secretion of matrix metalloproteinases and their inhibitors (tissue inhibitors of metalloproteinases) by human prostate explant cultures: reduced tissue inhibitor of metalloproteinase secretion by malignant tissues. " Cancer Res. 1993, 53: S.4493-4498.

88. Rasmussen HS, McCann PP: "Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat. " Pharmacol Ther. 1997, 75: S.69-75.

89. Knox JD, Bretton L, Lynch T, et al.: "Synthetic matrix metalloproteinase inhibitor, BB-94, inhibits the invasion of neoplastic human prostate cells in a mouse model. " Prostate. 1998, 35: S.248-254.

90. Wang X, Brown PD, Crimmin MJ, Hoffmann RM: "Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice. " Cancer Res. 1994, 54: S.4726-4728.

91. Botos I, Scapozza L, Zhang D, et al.: "Batimastat, a potent matrix metalloproteinase inhibitor, exhibits an unexpected mode of binding. " Proc Natl Acad Sci USA. 1996, 93: S.2749-2754.

92. Eccles SA, Box GM, Court WJ, et al.: "Control of lymphatic and hematogenous metastasis of a rat mammary carcinoma by the matrix metalloproteinase inhibitor batimastat (BB-94). " Cancer Res. 1996, 56: S.2815-2822.

93. 93. Boasberg P, Harbaugh B, Roth B, et al.: Marimastat, a novel matrix metalloproteinase inhibitor in patients with hormone-refractory prostate cancer. In: Proceedings of ASCO Thirty-Second Annual Meeting. 1996; 15: S.258.

94. Kager M, Spruss T, Schneider MR, von Angerer E : "Dunning R3327-G prostate carcinoma of the rat: an appropriate model for drug evaluation. " J Cancer Res Clin Oncol. 1992, 118: S.334-338.

95. Wilson MJ, Kapoor S, Vogel MM, Sinha AA: "Characterization of gelatin degrading metalloproteinase activities of the Dunning rat prostate tumor grown in nude mice. " Prostate. 1991, 19: S.237-250.

© Die inhaltliche Zusammenstellung und Aufmachung dieser Publikation sowie die elektronische Verarbeitung sind urheberrechtlich geschützt. Jede Verwertung, die nicht ausdrücklich vom Urheberrechtsgesetz zugelassen ist, bedarf der vorherigen Zustimmung. Das gilt insbesondere für die Vervielfältigung, die Bearbeitung und Einspeicherung und Verarbeitung in elektronische Systeme.